How to achieve a functional cure for chronic hepatitis B

Study published in the Journal of Hepatology shows increase in immune control after discontinuation of long-term antiviral therapy

2023-03-30

(Press-News.org) Geneva, March 30, 2023 – More than half of patients who suffer from chronic hepatitis B have the e antigen (HBeAg)-negative form of the disease. Even after many years of antiviral treatment with nucleos(t)ide analogues (NUC), lasting immune control is almost never seen. According to the current state of knowledge, those affected therefore require lifelong therapy. In the world’s first randomized controlled multicenter study – led by Leipzig University’s Faculty of Medicine and in partnership with the Centre for Clinical Studies (ZKS) – researchers have shown that many HBeAg-negative patients can achieve permanent immune control of hepatitis B if they discontinue antiviral therapy after a certain period of time. Their findings are published in the high-impact journal, the Journal of Hepatology.

Hepatitis B is an inflammation of the liver caused by the hepatitis B virus that can lead to serious problems such as liver cirrhosis or liver cancer and is easily transmitted through body fluids. An estimated 350 million are chronically infected, making chronic hepatitis B one of the most common viral infections worldwide. People with chronic hepatitis B usually have to take antiviral medication for their entire life in order to reduce the viral load and normalize inflammation levels in the liver. Antiviral therapy consists of the administration of nucleoside or nucleotide analogues, which in patients with the HBeAg-negative form almost never leads to the permanent immune control that would allow the termination of treatment. The antiviral therapy is associated with high costs for the healthcare system and can cause serious side effects.

Results currently published in the Journal of Hepatology show in a study of 166 HBeAg-negative patients from 20 clinics across Germany that after 96 weeks of observation many patients who discontinued an effective antiviral treatment that they had taken for at least four years achieved immune control of the disease. In 10% of the patients, immune control was demonstrated through loss of previously detectable hepatitis B surface antigen (HBsAg) in the blood, an event which is considered a functional cure of hepatitis B.

By the end of the study, in about 41% of patients, hepatitis B virus levels in the blood were reduced to below the level of 2,000 units per millilitre, which according to international treatment guidelines means that there is no longer an indication for renewed antiviral therapy. Additionally, 77% of patients no longer had elevated liver inflammation levels. In contrast, no patient who continued antiviral treatment showed HBsAg loss.

Study leader Professor Florian van Bömmel, senior physician in the Department of Hepatology at Leipzig University Hospital said, “We were able to show that in some patients discontinuing long-term therapy with nucleoside or nucleotide analogues after at least four years is more effective than continuing it, and that many patients no longer require antiviral therapy at all after discontinuation. In particular, patients who show low HBsAg levels when they discontinue treatment have a high chance of functional cure.”

After discontinuation of treatment, all of the patients initially experienced a resurgence of hepatitis B virus replication and many also experienced transient renewed liver inflammation. Some patients with severe liver inflammation were then restarted on antiviral therapy to prevent liver damage. Patients with liver cirrhosis were not included in the study for safety reasons. No serious adverse events related to discontinuation of therapy occurred during the study. “However, in other studies, severe cases of hepatic inflammation were observed in a few cases after antiviral therapy was discontinued. Stopping NUC treatment should therefore only be carried out under the supervision of an experienced physician,” said the study leader.

Professor van Bömmel and Professor Thomas Berg, head of the Department of Hepatology at Leipzig University Hospital, are confident that the results of the STOP-NUC trial will have a major impact on the overall development of hepatitis B therapy: “We expect that in the future international guidelines for the treatment of hepatitis B will refer to this study. By the middle of this year, results from the extension of the study will be evaluated and will show whether the number of patients with immune control continues to increase in the long term after discontinuation of antiviral treatment.”

END

[Attachments] See images for this press release:

How to achieve a functional cure for chronic hepatitis B 2

How to achieve a functional cure for chronic hepatitis B 3

ELSE PRESS RELEASES FROM THIS DATE:

New, exhaustive study probes hidden history of horses in the American West

2023-03-30

A team of international researchers has dug into archaeological records, DNA evidence and Indigenous oral traditions to paint what might be the most exhaustive history of early horses in North America to date. The group’s findings show that these beasts of burden may have spread throughout the American West much faster and earlier than many European accounts have suggested. The researchers, including several scientists from the University of Colorado Boulder, published their findings today in the journal Science. To tell the stories of horses in the West, the team closely examined about two dozen sets of ...

Newly discovered trigger for major depression opens new possibilities for treatments

2023-03-30

A common amino acid, glycine, can deliver a “slow-down” signal to the brain, likely contributing to major depression, anxiety and other mood disorders in some people, scientists at the Wertheim UF Scripps Institute for Biomedical Innovation & Technology have found. The discovery, outlined Thursday in the journal Science, improves understanding of the biological causes of major depression and could accelerate efforts to develop new, faster-acting medications for such hard-to-treat mood disorders, said neuroscientist Kirill Martemyanov, Ph.D., corresponding author of ...

Search for a major depression trigger reveals a familiar face: Discovery opens new possibilities for treatments

2023-03-30

JUPITER, Fla.— A common amino acid, glycine, can deliver a “slow-down” signal to the brain, likely influencing major depression, anxiety and other mood disorders in some people, scientists at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology report online in the journal Science today. The discovery improves understanding of the biological causes of major depression and could accelerate efforts to develop new, faster-acting medications for such hard-to-treat mood disorders, said neuroscientist Kirill Martemyanov, Ph.D., corresponding author of the study, appearing in Friday’s ...

AI predicts enzyme function better than leading tools

2023-03-30

CHAMPAIGN, Ill. — A new artificial intelligence tool can predict the functions of enzymes based on their amino acid sequences, even when the enzymes are unstudied or poorly understood. The researchers said the AI tool, dubbed CLEAN, outperforms the leading state-of-the-art tools in accuracy, reliability and sensitivity. Better understanding of enzymes and their functions would be a boon for research in genomics, chemistry, industrial materials, medicine, pharmaceuticals and more. “Just like ChatGPT uses data from written language to create predictive text, we are leveraging ...

Predatory dinosaurs such as T. rex sported lizard-like lips

2023-03-30

A new study suggests that predatory dinosaurs, such as Tyrannosaurus rex, did not have permanently exposed teeth as depicted in films such as Jurassic Park, but instead had scaly, lizard-like lips covering and sealing their mouths. Researchers and artists have debated whether theropod dinosaurs, the group of two-legged dinosaurs that includes carnivores and top predators like T. rex and Velociraptor, as well as birds, had lipless mouths where perpetually visible upper teeth hung over their lower jaws, similar to the mouth of a crocodile. However, an international team of researchers challenge some of the best-known depictions, and say these dinosaurs had lips similar to those ...

Moiré superlattices show superpower in photonics and optoelectronics

2023-03-30

Researchers from the Institute of Physics (IOP) of the Chinese Academy of Sciences, collaborating with international colleagues, have presented an overview of recent progress in emerging moiré photonics and optoelectronics. The review was published in Science on March 30. Moiré superlattices are artificial quantum materials formed by vertically stacking two or more two-dimensional (2D) layered materials with a slight lattice mismatch and/or a small rotational twist. They introduce a potential landscape of much larger length scale than the crystal periodicity ...

Increasing availability of non-alcoholic drinks may reduce amount of alcohol purchased online

2023-03-30

Increasing the proportion of non-alcoholic drinks on sale in online supermarkets could reduce the amount of alcohol people purchase, suggests a study published today led by researchers at the University of Cambridge. The team used a simulated supermarket that presented shoppers with varying proportions of alcoholic and non-alcoholic drinks and asked them to select drinks to purchase for their next online shop. They found that shoppers who were exposed to more non-alcoholic drinks selected and purchased fewer units of alcohol. The findings are published in PLOS Medicine. Excessive ...

The untold history of the horse in the American Plains, a new future for the world

2023-03-30

“Horses have been part of us since long before other cultures came to our lands, and we are a part of them,” states Chief Joe American Horse, a leader of the Oglala Lakota Oyate, traditional knowledge keeper, and co-author of the study. In 2018, at the instruction of her elder knowledge keepers and traditional leaders, Dr. Yvette Running Horse Collin contacted Prof Ludovic Orlando, French National Centre for Scientific Research (CNRS) scientist. She had completed her PhD, which focused on deconstructing the history of horses in the Americas. Up until that point, the field had been dominated by western academics, and Indigenous voices had been largely dismissed. She sought ...

T cells in human blood secrete a substance that affects blood pressure and inflammation

2023-03-30

Acetylcholine regulates blood flow, but the source of blood acetylcholine has been unclear. Now, researchers at Karolinska Institutet have discovered that certain T cells in human blood can produce acetylcholine, which may help regulate blood pressure and inflammation. The study, which is published in PNAS, also demonstrates a possible association between these immune cells in seriously ill patients and the risk of death. Blood flow regulation by acetylcholine is long established and highlighted by the 1998 Nobel Prize in Physiology or Medicine. Yet the sources of acetylcholine ...

Interviews with icons yield lessons on productivity in ‘Wisdom Years’

2023-03-30

The Wonder Years can be great, sure: first loves, long summers, panoramic dreams exclusive to those with a lifetime of runway. The Working Years, too: established identity, new family and old friends, freedom to pursue personal goals and professional satisfaction. The University of Nebraska–Lincoln’s Ken Kiewra just doesn’t want you to forget about the Wisdom Years. They got the name from famed psychologist Erik Erikson, who roughly defined them as starting at age 65, often considered a mile-marker of retirement in the United States. But whereas Erikson saw the Wisdom Years as ...

How to achieve a functional cure for chronic hepatitis B

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: